SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Korsana Biosciences Reports Third-Quarter 2026 EPS of ($3.19)

Korsana reported a wider third-quarter net loss as research and development and general and administrative expenses increased. Higher costs included stock-based compensation, spending on undisclosed programs, and personnel-related and chemistry, manufacturing and development costs.

KRSA

Related stories